MedPage Today1h
FDA Staff Not Quite Sold on Sotagliflozin for T1D Patients With CKD
Sotagliflozin has faced a difficult path in T1D. The FDA rejected the drug 5 years ago as an adjunct to insulin for adults ...
FDA expands recall of Dynacare baby powder, sent to IL, IN, WI, due to possible asbestos risk
The Food and Drug administration has expanded a recall of Dynacare baby powder, made by the Dynarex Corporation. The recall ...
Hims & Hers stock falls 14% after FDA changes semaglutide supply status (update)
Hims & Hers (HIMS) stock fell 14% following news that Novo Nordisk’s (NVO) weight-loss drug Wegovy is no longer ...
FDA-approved procedure helps regrow knee cartilage, easing pain
Dr. Rick Lehman performs the MACI procedure, which uses the patient's own cells to regrow cartilage in the knee, eliminating ...
oncnursingnews4h
October 2024 FDA Approvals for Oncology
October 2024 brought 4 new FDA drug approvals in the oncology space. With new drug regimens in both the solid tumor and blood ...
Managed Healthcare Executive3h
FDA Accepts Organon’s Application for Prolia Biosimilar
Regulators are also reviewing Teva’s application for its Prolia biosimilar candidate. The FDA’s decisions are expected ...
Targeted Oncology2h
FDA Issues Warning on BioZorb Markers After Recall Due to Patient Complications
Providers advised to halt use, monitor patients, and report any complications with BioZorb devices to the FDA.